Latest news with #EMG
Yahoo
5 days ago
- Business
- Yahoo
Are Wall Street Analysts Predicting AMETEK Stock Will Climb or Sink?
With a market cap of $43.2 billion, AMETEK, Inc. (AME) is a global leader in manufacturing advanced electronic instruments and electromechanical devices. The company operates through two segments: Electronic Instruments Group (EIG) and Electromechanical Group (EMG), serving diverse industries including aerospace, defense, medical, industrial, and power. Shares of the Berwyn, Pennsylvania-based company have underperformed the broader market over the past 52 weeks. AME stock has increased 15.9% over this time frame, while the broader S&P 500 Index ($SPX) has returned nearly 19%. Moreover, shares of AMETEK are up 3.7% on a YTD basis, compared to SPX's nearly 10% gain. More News from Barchart Why This Cannabis Penny Stock Could Be Wall Street's Next Meme Trade Breakout Apple Stock Is Gaining Momentum, Is AAPL Stock a Buy? Peter Thiel-Backed Bullish Is About to IPO. Should You Buy BLSH Stock? Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! Focusing more closely, the industrial tools maker stock has also lagged behind the Industrial Select Sector SPDR Fund's (XLI) 20.7% return over the past 52 weeks. Shares of AMETEK jumped 4.6% on Jul. 31 after the company posted stronger-than-expected Q2 2025 results, with adjusted EPS of $1.78 and revenue of $1.8 billion. Growth was driven by a 6% year-over-year sales increase in the Electromechanical Group (EMG) to $618.5 million, supported by strong organic demand, record operating income, robust margin expansion, and contributions from the recent FARO Technologies acquisition. The company also raised its 2025 adjusted EPS forecast to $7.06 - $7.20 and now expects annual sales growth in the mid-single digits versus its prior low-single-digit outlook. For the fiscal year ending in December 2025, analysts expect AMETEK's adjusted EPS to grow 4.5% year-over-year to $7.14. The company's earnings surprise history is promising. It topped the consensus estimates in the last four quarters. Among the 17 analysts covering the stock, the consensus rating is a 'Moderate Buy.' That's based on 11 'Strong Buy' ratings, one 'Moderate Buy,' four 'Holds,' and one 'Strong Sell.' On Aug. 1, Mizuho raised Ametek's price target to $225 and maintained an 'Outperform' rating. As of writing, the stock is trading below the mean price target of $207. The Street-high price target of $225 implies a potential upside of 21.4% from the current price levels. On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
See - Sada Elbalad
7 days ago
- Health
- See - Sada Elbalad
Tunisian Startup Revolutionizes Prosthetics with AI-Powered Bionic Limbs
Israa Farhan A Tunisian medtech startup based in the coastal city of Sousse is transforming the future of prosthetics by developing lightweight, AI-powered bionic arms that combine cutting-edge engineering with affordability. Founded in early 2020 by engineer Mohamed Dhaouafi, Cure Bionics produces 3D-printed prosthetic limbs controlled by muscle signals through advanced electromyography (EMG) sensors. The company's mission is to make high-quality prosthetics accessible, particularly for children, at a fraction of the cost of imported alternatives. Dhaouafi said the idea was born during his studies at the National Engineering School of Sousse, when a student competition led to a life-changing project. A teammate's relative was born with a congenital limb difference but could not afford a prosthetic until she was 20, and even then, the options were prohibitively expensive or unavailable locally. This inspired the team to design affordable, high-performance bionic limbs and rehabilitation solutions. Unlike traditional prosthetics, which can cost up to 50,000 US dollars and take months to manufacture, Cure Bionics' arm prostheses are ready within a week and priced around 8,000 US dollars. Intensive care medicine professor Amine Allah Massadi from the University of Tunis notes that these bionic limbs deliver advanced technical performance at 50% or more below the cost of comparable foreign products. Inside the company's lab, engineers scan patient limbs using the Myo Finder device, which reads EMG signals in real time. Users, like Yassine Jarsa, train via the Myo Link mobile app, which simulates bionic hand control in 2D before fitting the actual device. The company's flagship prosthetic arm, named Hannibal, offers a suite of features tailored to amputees' needs. It includes a rotating wrist joint, an adjustable socket, magnetic charging to eliminate battery removal, and tactile feedback for partial sensation restoration. With a simple mode-switch button, users can alternate between assistive and automatic functions, lock movement, and even feel vibrations that simulate touch. read more UAE's Lunar Mission Delayed to Tomorrow Twitter Lifts Trump's Account Ban Scientists Find Evidence Of 10،000 Black Holes Surrounding The Center Of The Milky Way Galaxy Greenhouse In Antarctica Able To Grow Vegetables Without Soil Or Sunlight Moving Over China: U.S. Is Again Home to World's Speediest Supercomputer Technology The 10 most expensive cars in the world Technology Top 10 fastest cars in the world Technology Lasers Could Make Computers 1 Million Times Faster Technology Smart technology taking control of our lives Videos & Features Story behind Trending Jessica Radcliffe Death Video News Israeli-Linked Hadassah Clinic in Moscow Treats Wounded Iranian IRGC Fighters Arts & Culture "Jurassic World Rebirth" Gets Streaming Date News China Launches Largest Ever Aircraft Carrier News Ayat Khaddoura's Final Video Captures Bombardment of Beit Lahia Business Egyptian Pound Undervalued by 30%, Says Goldman Sachs Videos & Features Tragedy Overshadows MC Alger Championship Celebration: One Fan Dead, 11 Injured After Stadium Fall Arts & Culture South Korean Actress Kang Seo-ha Dies at 31 after Cancer Battle Lifestyle Get to Know 2025 Eid Al Adha Prayer Times in Egypt Arts & Culture Lebanese Media: Fayrouz Collapses after Death of Ziad Rahbani
Yahoo
10-08-2025
- Business
- Yahoo
7.6% dividend yield but down 25%! Could this be a FTSE bargain to snap up now?
Even as UK shares reach record highs, there are still plenty of juicy dividend yields to capitalise on. And some have started venturing closer to double-digit territory. Investing in high-yield stocks requires vigilance. After all, not every chunky payout's sustainable. And investing in a business that's later forced to cut dividends seldom ends well. With that in mind, let's take a closer look at an unloved FTSE 250 firm – Man Group (LSE:EMG) with its 7.6% dividend income offer. Investigating the yield Over the last 12 months, the shares of this asset management firm haven't been on a great run. In fact, they're down by roughly 25% since last August, which is why the stock now offers such an impressive yield. The problem lies with its performance fees, or rather, the lack of them. With the financial markets experiencing turmoil, Man Group's active investing strategies have struggled to deliver market-beating returns across its various funds. As such, despite assets under management actually climbing to record highs, its core pre-tax profits took a nasty 43% hit in its latest interim results. This perfectly highlights the company's dependence on its volatile performance fees compared to other asset managers who typically rely on more stable management fees. This makes the firm's cash flow far more challenging to predict while also making the dividend susceptible to market shocks. So far, the company's managed to maintain and expand shareholder payouts for the last five years despite the challenges endured along the way. But with growing macroeconomic pressure, client loyalty and stickiness may soon be getting tested, putting today's high dividend yield at risk. Room for optimism While Man Group's recent performance leaves much to be desired, there are still some encouraging trends hiding under the surface. As previously mentioned, despite the challenges, the company's continued to attract fresh client funds, pushing assets under management higher. That's important given that a stabilisation of market volatility and the emergence of new opportunities could create some lucrative returns for its active funds. And, in turn, deliver a substantial rebound in performance fees that could send both earnings and the share price flying. The balance sheet also appears to be in a relatively healthy state with a net cash position. And management also has access to a large undrawn revolving credit facility, granting ample short-term liquidity to support its now elevated dividend yield while awaiting a profit rebound. The bottom line All things considered, Man Group seems to offer a unique blend of growth, income and value opportunity for investors. The discounted valuation could make buying shares today a highly lucrative decision if the company's successful in restoring its performance fee income. However, there's no denying this comes with significant risks. The stock will likely remain volatile and dependent on its active funds' performance, something that management doesn't have a great deal of control over. After all, the stock market's notoriously unpredictable in the short term. With that in mind, even with a 7.6% dividend, this isn't a stock I'm rushing to buy today. The post 7.6% dividend yield but down 25%! Could this be a FTSE bargain to snap up now? appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Sign in to access your portfolio
Associated Press
03-08-2025
- Health
- Associated Press
Hands-On Diagnostics Announces Annual Symposium to Help Physical Therapists Improve Patient Outcomes
Join leading PTs October 18–19 at APTA HQ to learn how EMG and MSK ultrasound can improve outcomes and boost clinic revenue—no prior training required. 'This symposium gives every PT the tools to think diagnostically, treat with precision, and lead with confidence.'— Dr. Konstantine Rizopoulos, Co-Founder Hands-On Diagnostics ASTORIA, NY, UNITED STATES, August 3, 2025 / / -- Hands-On Diagnostics (HODS) proudly announces the 12th Annual HODS Symposium, taking place October 18–19, 2025, at the APTA Headquarters in Alexandria, Virginia. This year's event is specifically designed for physical therapists who are not trained in electromyography (EMG) or musculoskeletal ultrasound (MSKUS) but want to harness diagnostic findings to create more effective treatment plans and deliver better patient outcomes. With the theme 'Primary Care Physical Therapy: Mastering Diagnostics, Manual Therapy, and Advanced Interventions,' the 2025 symposium marks a pivotal opportunity for clinicians ready to embrace the next level of practice. Recent research confirms that EMG and MSK ultrasound shift patient management decisions in over 60% of cases—resulting in dramatically improved clinical outcomes. These are not abstract theories. They are evidence-based tools that are reshaping how physical therapists diagnose, treat, and lead in today's evolving healthcare environment. At this two-day, high-impact event, attendees will: • Learn how integrating diagnostics with manual therapy improves outcomes by more than 60% • Discover how real-world clinics are using diagnostics to drive 30%+ revenue growth • Gain a step-by-step implementation roadmap—with no prior experience required • Participate in hands-on workshops and live demonstrations of EMG, MSK ultrasound, and treatment techniques • Analyze actual clinical cases and walk away with skills they can apply immediately • Earn up to 13.75 contact hours, with both live and virtual attendance options available The program features nationally recognized experts in diagnostic testing, manual therapy, and neuro-musculoskeletal care. Whether addressing shoulder pain, back pain, radiculopathy, tendinopathy, or sports injuries, clinicians will leave the symposium with practical, effective strategies that can be applied the very next day. Key sessions include: • Diagnosis and treatment of cervical and lumbar radiculopathy using EMG and spinal mobilization • Segment-specific thrust manipulation guided by electrodiagnostic findings • Neural mobilization based on neuro-MSK ultrasound and EMG • Dry needling under MSKUS guidance • Neuro-MSK imaging workshops • Somatosensory evoked potentials (SSEP) for PT practice • Direction-sensitive spinal mobilization using H-Reflex This year's symposium also features special sessions on launching and growing a diagnostic practice, offering practical business strategies to build a practice that stands out through clinical excellence, operational efficiency, and enhanced profitability. Designed for clinicians, private practice owners, and decision-makers, the 2025 HODS Symposium is a must-attend event for anyone seeking to elevate their practice and outcomes through diagnostic insight. Registration is now open at In-person and virtual ticket options are available. Attendees are encouraged to bring their clinical and administrative team members to take full advantage of the event's educational and strategic sessions. Master the science. Apply the skill. Transform your practice. Dimitrios Kostopoulos Hands-On Diagnostics +1 917-538-2242 email us here Visit us on social media: LinkedIn Facebook YouTube X Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Yahoo
02-08-2025
- Business
- Yahoo
We Wouldn't Be Too Quick To Buy Man Group Plc (LON:EMG) Before It Goes Ex-Dividend
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Man Group Plc (LON:EMG) is about to trade ex-dividend in the next four days. Typically, the ex-dividend date is two business days before the record date, which is the date on which a company determines the shareholders eligible to receive a dividend. The ex-dividend date is an important date to be aware of as any purchase of the stock made on or after this date might mean a late settlement that doesn't show on the record date. Thus, you can purchase Man Group's shares before the 7th of August in order to receive the dividend, which the company will pay on the 19th of September. The company's next dividend payment will be US$0.057 per share, and in the last 12 months, the company paid a total of US$0.17 per share. Looking at the last 12 months of distributions, Man Group has a trailing yield of approximately 7.9% on its current stock price of UK£1.634. If you buy this business for its dividend, you should have an idea of whether Man Group's dividend is reliable and sustainable. As a result, readers should always check whether Man Group has been able to grow its dividends, or if the dividend might be cut. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Dividends are typically paid out of company income, so if a company pays out more than it earned, its dividend is usually at a higher risk of being cut. Last year, Man Group paid out 108% of its income as dividends, which is above a level that we're comfortable with, especially if the company needs to reinvest in its business. When a company pays out a dividend that is not well covered by profits, the dividend is generally seen as more vulnerable to being cut. Check out our latest analysis for Man Group Click here to see the company's payout ratio, plus analyst estimates of its future dividends. Have Earnings And Dividends Been Growing? Companies with falling earnings are riskier for dividend shareholders. Investors love dividends, so if earnings fall and the dividend is reduced, expect a stock to be sold off heavily at the same time. That's why it's not ideal to see Man Group's earnings per share have been shrinking at 2.8% a year over the previous five years. Many investors will assess a company's dividend performance by evaluating how much the dividend payments have changed over time. Man Group has delivered 5.5% dividend growth per year on average over the past 10 years. That's intriguing, but the combination of growing dividends despite declining earnings can typically only be achieved by paying out a larger percentage of profits. Man Group is already paying out 108% of its profits, and with shrinking earnings we think it's unlikely that this dividend will grow quickly in the future. Final Takeaway Should investors buy Man Group for the upcoming dividend? Earnings per share are in decline and Man Group is paying out what we feel is an uncomfortably high percentage of its profit as dividends. It's not that we hate the business, but we feel that these characeristics are not desirable for investors seeking a reliable dividend stock to own for the long term. This is not an overtly appealing combination of characteristics, and we're just not that interested in this company's dividend. With that being said, if you're still considering Man Group as an investment, you'll find it beneficial to know what risks this stock is facing. For example - Man Group has 3 warning signs we think you should be aware of. Generally, we wouldn't recommend just buying the first dividend stock you see. Here's a curated list of interesting stocks that are strong dividend payers. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
